WO2021000885A1 - Dérivés de quinazoline, leur procédé de préparation et leur utilisation médicale - Google Patents
Dérivés de quinazoline, leur procédé de préparation et leur utilisation médicale Download PDFInfo
- Publication number
- WO2021000885A1 WO2021000885A1 PCT/CN2020/099690 CN2020099690W WO2021000885A1 WO 2021000885 A1 WO2021000885 A1 WO 2021000885A1 CN 2020099690 W CN2020099690 W CN 2020099690W WO 2021000885 A1 WO2021000885 A1 WO 2021000885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- pharmaceutically acceptable
- cycloalkyl
- compound
- atropisomer
- Prior art date
Links
- 0 CC*N1C2C1C2 Chemical compound CC*N1C2C1C2 0.000 description 9
- CAFARZLXMKGTQP-DKKDMOBXSA-N C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-6)c5N4c4c3c2c(C)c-6n4)N1C(C=C)=O Chemical compound C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-6)c5N4c4c3c2c(C)c-6n4)N1C(C=C)=O CAFARZLXMKGTQP-DKKDMOBXSA-N 0.000 description 3
- KFKQAZUPEFSMAP-GMAHTHKFSA-N CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(C=C)=O)-c2c(cn[nH]4)c4ccc2C)c1C3=N1)C1=O Chemical compound CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(C=C)=O)-c2c(cn[nH]4)c4ccc2C)c1C3=N1)C1=O KFKQAZUPEFSMAP-GMAHTHKFSA-N 0.000 description 2
- DJXWXNNIXHWVDR-QWAKEFERSA-N CC(c(cccc1)c1N12)[O]=C1N=C1N(CCN(C3)C(OC(C)(C)C)=O)[C@@H]3COc3cc(B4OC(C)(C)C(C)(C)O4)cc2c13 Chemical compound CC(c(cccc1)c1N12)[O]=C1N=C1N(CCN(C3)C(OC(C)(C)C)=O)[C@@H]3COc3cc(B4OC(C)(C)C(C)(C)O4)cc2c13 DJXWXNNIXHWVDR-QWAKEFERSA-N 0.000 description 2
- IPGZFBIYTPSQAR-MDNYFUNBSA-N C[C@@H](CN(C(C1)(C2)C1O1)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-c6n7)c5N4c7c3c1c6Cl)N2C(C=C)=O Chemical compound C[C@@H](CN(C(C1)(C2)C1O1)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-c6n7)c5N4c7c3c1c6Cl)N2C(C=C)=O IPGZFBIYTPSQAR-MDNYFUNBSA-N 0.000 description 2
- OCRHRSROOZDUMT-UHFFFAOYSA-N C(CNC1)C11CSCC1 Chemical compound C(CNC1)C11CSCC1 OCRHRSROOZDUMT-UHFFFAOYSA-N 0.000 description 1
- ZFXLXFRHCNGOCV-UPVQGACJSA-N CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(OC(C)(C)C)=O)-c2c(cn[nH]4)c4ccc2C)c1C3=N1)C1=O Chemical compound CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(OC(C)(C)C)=O)-c2c(cn[nH]4)c4ccc2C)c1C3=N1)C1=O ZFXLXFRHCNGOCV-UPVQGACJSA-N 0.000 description 1
- WAEAIGDEVQGZPE-HKUYNNGSSA-N CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(OC(C)(C)C)=O)Br)c1C3=N1)C1=O Chemical compound CC(C)c(cccc1)c1N(c(cc(cc1OC[C@H](C2)N3C[C@H](C)N2C(OC(C)(C)C)=O)Br)c1C3=N1)C1=O WAEAIGDEVQGZPE-HKUYNNGSSA-N 0.000 description 1
- URWNBBMJCRZPEX-UHFFFAOYSA-N CC(C)c(cccc1)c1NC(NC(c(c(F)cc(Br)c1)c1F)=O)=O Chemical compound CC(C)c(cccc1)c1NC(NC(c(c(F)cc(Br)c1)c1F)=O)=O URWNBBMJCRZPEX-UHFFFAOYSA-N 0.000 description 1
- FNQHVTFYEIVDAB-FQEVSTJZSA-N CC(C)c(ncnc1C(C)C)c1N(c(cc(cc1OC[C@H](C2)N3CCN2C(C=C)=O)-c(c(F)ccc2)c2N)c1C3=N1)C1=O Chemical compound CC(C)c(ncnc1C(C)C)c1N(c(cc(cc1OC[C@H](C2)N3CCN2C(C=C)=O)-c(c(F)ccc2)c2N)c1C3=N1)C1=O FNQHVTFYEIVDAB-FQEVSTJZSA-N 0.000 description 1
- NLYJEOQVFQXCMX-HKUYNNGSSA-N CC(C)c1ccccc1N(c(cc(cc1OC[C@H](C2)NC[C@H](C)N2C(OC(C)(C)C)=O)Br)c1C(N1)=O)C1=O Chemical compound CC(C)c1ccccc1N(c(cc(cc1OC[C@H](C2)NC[C@H](C)N2C(OC(C)(C)C)=O)Br)c1C(N1)=O)C1=O NLYJEOQVFQXCMX-HKUYNNGSSA-N 0.000 description 1
- QFBSPLHYDWREHW-UHFFFAOYSA-N CC(C1OCC(C2)N3CCN2C(C=C)=O)C(c2cccc4c2c(C)ccc4)=CC(N2c4c(C)cccc4)=C1C3=NC2=O Chemical compound CC(C1OCC(C2)N3CCN2C(C=C)=O)C(c2cccc4c2c(C)ccc4)=CC(N2c4c(C)cccc4)=C1C3=NC2=O QFBSPLHYDWREHW-UHFFFAOYSA-N 0.000 description 1
- GIFMRZAPTFJETJ-YMRFRXFKSA-N CC(c(cccc1)c1N1)/[O]=C(\C)/N=C2/N(CCNC3)[C@@H]3COc3cc(-c(c(N)ccc4Cl)c4F)cc1c23 Chemical compound CC(c(cccc1)c1N1)/[O]=C(\C)/N=C2/N(CCNC3)[C@@H]3COc3cc(-c(c(N)ccc4Cl)c4F)cc1c23 GIFMRZAPTFJETJ-YMRFRXFKSA-N 0.000 description 1
- KURCTAJZVRTUEU-NNBQYGFHSA-N CC(c(cccc1)c1N12)[O]=C1N=C1N(CCN(C3)C(OC(C)(C)C)=O)[C@@H]3COc3cc(-c(c(N)ncc4)c4F)cc2c13 Chemical compound CC(c(cccc1)c1N12)[O]=C1N=C1N(CCN(C3)C(OC(C)(C)C)=O)[C@@H]3COc3cc(-c(c(N)ncc4)c4F)cc2c13 KURCTAJZVRTUEU-NNBQYGFHSA-N 0.000 description 1
- ISZUCTGAAABYER-WMCAAGNKSA-N CC(c(cccc1)c1N12)[O]=C1N=C1N(CCNC3)[C@@H]3COc3cc(-c(c(N)ccc4Cl)c4F)cc2c13 Chemical compound CC(c(cccc1)c1N12)[O]=C1N=C1N(CCNC3)[C@@H]3COc3cc(-c(c(N)ccc4Cl)c4F)cc2c13 ISZUCTGAAABYER-WMCAAGNKSA-N 0.000 description 1
- BRWJNJIQOZJQJB-WMCAAGNKSA-N CC(c(cccc1)c1N12)[O]=C1N=C1N(CCNC3)[C@@H]3COc3cc(-c(c(N)ncc4)c4F)cc2c13 Chemical compound CC(c(cccc1)c1N12)[O]=C1N=C1N(CCNC3)[C@@H]3COc3cc(-c(c(N)ncc4)c4F)cc2c13 BRWJNJIQOZJQJB-WMCAAGNKSA-N 0.000 description 1
- WEVJOWHMTUEFQU-VOTSOKGWSA-N CC/C(/F)=C\C(C)(C)C Chemical compound CC/C(/F)=C\C(C)(C)C WEVJOWHMTUEFQU-VOTSOKGWSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- RGIMMKBGYMLIOF-UHFFFAOYSA-N CCC(Nc(c(Cl)ccc1F)c1Br)=C Chemical compound CCC(Nc(c(Cl)ccc1F)c1Br)=C RGIMMKBGYMLIOF-UHFFFAOYSA-N 0.000 description 1
- CTGISLSANHYMQU-UPVQGACJSA-N CC[C@@H](COc1cc(-c2c(cn[nH]3)c3ccc2C)cc(N2c3c(C(C)C)cccc3)c11)N(C[C@H](C)NC(C=C)=O)C1=NC2=O Chemical compound CC[C@@H](COc1cc(-c2c(cn[nH]3)c3ccc2C)cc(N2c3c(C(C)C)cccc3)c11)N(C[C@H](C)NC(C=C)=O)C1=NC2=O CTGISLSANHYMQU-UPVQGACJSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- OIJZOCGITUSGNE-SMEJFCCLSA-N C[C@@H](C1)NC[C@H](CO2)N1C1=NC3=[O]C(C)c(cccc4Oc5cccc(F)c5-c5n6)c4N3c6c1c2c5Cl Chemical compound C[C@@H](C1)NC[C@H](CO2)N1C1=NC3=[O]C(C)c(cccc4Oc5cccc(F)c5-c5n6)c4N3c6c1c2c5Cl OIJZOCGITUSGNE-SMEJFCCLSA-N 0.000 description 1
- OJOGOCAMEPJUOB-DLDKDUQYSA-N C[C@@H](CN([C@@H](CO)C1)C2=NC3=[O]C(C)c(cccc4C)c4N3c(nc3Cl)c2c(Cl)c3Cl)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN([C@@H](CO)C1)C2=NC3=[O]C(C)c(cccc4C)c4N3c(nc3Cl)c2c(Cl)c3Cl)N1C(OC(C)(C)C)=O OJOGOCAMEPJUOB-DLDKDUQYSA-N 0.000 description 1
- YRYUMSJQBQFHOM-RPCGPGEBSA-N C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-c6n7)c5N4c7c3c2c6Cl)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c(cccc5Oc6cccc(F)c6-c6n7)c5N4c7c3c2c6Cl)N1C(OC(C)(C)C)=O YRYUMSJQBQFHOM-RPCGPGEBSA-N 0.000 description 1
- VCKBYZCUOQBZGG-DLDKDUQYSA-N C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c5cccc(C)c5N4c(nc4Cl)c3c2c4Cl)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN([C@H](C1)CO2)C3=NC4=[O]C(C)c5cccc(C)c5N4c(nc4Cl)c3c2c4Cl)N1C(OC(C)(C)C)=O VCKBYZCUOQBZGG-DLDKDUQYSA-N 0.000 description 1
- OCHKRKFPKUAHGF-DTWKUNHWSA-N C[C@@H](CN[C@@H](CO)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN[C@@H](CO)C1)N1C(OC(C)(C)C)=O OCHKRKFPKUAHGF-DTWKUNHWSA-N 0.000 description 1
- OCHKRKFPKUAHGF-IUCAKERBSA-N C[C@@H](CN[C@H](CO)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN[C@H](CO)C1)N1C(OC(C)(C)C)=O OCHKRKFPKUAHGF-IUCAKERBSA-N 0.000 description 1
- MAGVYDSTMGEBKN-IKCNDWCXSA-N C[C@H](CN([C@@H](C1)CO2)C3=NC4=[O]C(C)c5ccccc5N4c4c3c2cc(-c(c(N)ccc2)c2F)c4)N1C(C=C)=O Chemical compound C[C@H](CN([C@@H](C1)CO2)C3=NC4=[O]C(C)c5ccccc5N4c4c3c2cc(-c(c(N)ccc2)c2F)c4)N1C(C=C)=O MAGVYDSTMGEBKN-IKCNDWCXSA-N 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N Cc(cccc1)c1N Chemical compound Cc(cccc1)c1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- MEAPLLXCNISMJS-UHFFFAOYSA-N Cc(cccc1)c1N(c(cc(cc1OCC(C2)NCCN2Br)Br)c1C(N1)=O)C1=O Chemical compound Cc(cccc1)c1N(c(cc(cc1OCC(C2)NCCN2Br)Br)c1C(N1)=O)C1=O MEAPLLXCNISMJS-UHFFFAOYSA-N 0.000 description 1
- BLSVCHHBHKGCSQ-UHFFFAOYSA-N Cc(cccc1)c1NC(N)=O Chemical compound Cc(cccc1)c1NC(N)=O BLSVCHHBHKGCSQ-UHFFFAOYSA-N 0.000 description 1
- KOAZIBHMVKZRQV-UHFFFAOYSA-N Cc1cccc2c1c(-c(cc1OCC(C3)N4CCN3C(C=C)=O)cc(N3c5c(C6CC6)cccc5)c1C4=NC3=O)ccc2 Chemical compound Cc1cccc2c1c(-c(cc1OCC(C3)N4CCN3C(C=C)=O)cc(N3c5c(C6CC6)cccc5)c1C4=NC3=O)ccc2 KOAZIBHMVKZRQV-UHFFFAOYSA-N 0.000 description 1
- IOOHLHPTFHYPSD-UHFFFAOYSA-N Nc(c(Br)c1F)ccc1Cl Chemical compound Nc(c(Br)c1F)ccc1Cl IOOHLHPTFHYPSD-UHFFFAOYSA-N 0.000 description 1
- DYQZJWKZFRTCET-UHFFFAOYSA-N Nc(nccc1F)c1Br Chemical compound Nc(nccc1F)c1Br DYQZJWKZFRTCET-UHFFFAOYSA-N 0.000 description 1
- XZRSXRUYZXBTGD-UHFFFAOYSA-N Nc1cccc(F)c1Br Chemical compound Nc1cccc(F)c1Br XZRSXRUYZXBTGD-UHFFFAOYSA-N 0.000 description 1
- FPXQHZPCFRQWCP-UHFFFAOYSA-N OB(c(c(O)ccc1)c1F)O Chemical compound OB(c(c(O)ccc1)c1F)O FPXQHZPCFRQWCP-UHFFFAOYSA-N 0.000 description 1
- DAZIOVACRMBMPB-SCSAIBSYSA-N OC[C@H](C(NC12CC1)=O)NC2=O Chemical compound OC[C@H](C(NC12CC1)=O)NC2=O DAZIOVACRMBMPB-SCSAIBSYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Abstract
L'invention concerne un dérivé de quinazoline tel que représenté par la formule générale (I), son procédé de préparation, une composition pharmaceutique contenant le dérivé et l'utilisation du dérivé en tant qu'agent thérapeutique, en particulier en tant qu'inhibiteur de KRAS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080045383.8A CN114040914A (zh) | 2019-07-01 | 2020-07-01 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910584947 | 2019-07-01 | ||
CN201910584947.4 | 2019-07-01 | ||
CN202010074335.3 | 2020-01-22 | ||
CN202010074335 | 2020-01-22 | ||
CN202010277887.4 | 2020-04-10 | ||
CN202010277887 | 2020-04-10 | ||
CN202010362869.6 | 2020-04-30 | ||
CN202010362869 | 2020-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021000885A1 true WO2021000885A1 (fr) | 2021-01-07 |
Family
ID=74100226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/099690 WO2021000885A1 (fr) | 2019-07-01 | 2020-07-01 | Dérivés de quinazoline, leur procédé de préparation et leur utilisation médicale |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN114040914A (fr) |
TW (1) | TW202115089A (fr) |
WO (1) | WO2021000885A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112390818A (zh) * | 2019-08-12 | 2021-02-23 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途 |
CN113980032A (zh) * | 2020-07-27 | 2022-01-28 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
WO2022251296A1 (fr) * | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Inhibiteurs de kras tricycliques hétéroaromatiques contenant du soufre |
WO2022268051A1 (fr) | 2021-06-21 | 2022-12-29 | 江苏恒瑞医药股份有限公司 | Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine |
US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2023001141A1 (fr) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Inhibiteurs de kras g12d et leurs utilisations |
WO2023031781A1 (fr) | 2021-09-01 | 2023-03-09 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
WO2023066371A1 (fr) * | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | Composé tétracyclique contenant de l'azote, son procédé de préparation et son utilisation médicale |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
WO2024022471A1 (fr) * | 2022-07-28 | 2024-02-01 | 上海湃隆生物科技有限公司 | Composé inhibiteur de kras |
US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
CN108779097A (zh) * | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
WO2018206539A1 (fr) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Composés hétéroaryle inhibant des protéines ras portant la mutation g12c |
CN109843856A (zh) * | 2016-05-18 | 2019-06-04 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
WO2020221239A1 (fr) * | 2019-04-28 | 2020-11-05 | 劲方医药科技(上海)有限公司 | Composé oxaazaquinazoline-7(8h)-cétone, son procédé de préparation et son application pharmaceutique |
-
2020
- 2020-07-01 TW TW109122320A patent/TW202115089A/zh unknown
- 2020-07-01 WO PCT/CN2020/099690 patent/WO2021000885A1/fr active Application Filing
- 2020-07-01 CN CN202080045383.8A patent/CN114040914A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
CN108779097A (zh) * | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
CN109843856A (zh) * | 2016-05-18 | 2019-06-04 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
WO2018206539A1 (fr) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Composés hétéroaryle inhibant des protéines ras portant la mutation g12c |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
US11548888B2 (en) | 2019-01-10 | 2023-01-10 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
CN112390818B (zh) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途 |
CN112390818A (zh) * | 2019-08-12 | 2021-02-23 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途 |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
US11964989B2 (en) | 2019-08-29 | 2024-04-23 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
CN113980032A (zh) * | 2020-07-27 | 2022-01-28 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
WO2022251296A1 (fr) * | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Inhibiteurs de kras tricycliques hétéroaromatiques contenant du soufre |
WO2022268051A1 (fr) | 2021-06-21 | 2022-12-29 | 江苏恒瑞医药股份有限公司 | Composé tétracyclique fusionné, son procédé de préparation et son utilisation en médecine |
WO2023001141A1 (fr) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Inhibiteurs de kras g12d et leurs utilisations |
WO2023031781A1 (fr) | 2021-09-01 | 2023-03-09 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
WO2023066371A1 (fr) * | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | Composé tétracyclique contenant de l'azote, son procédé de préparation et son utilisation médicale |
WO2024022471A1 (fr) * | 2022-07-28 | 2024-02-01 | 上海湃隆生物科技有限公司 | Composé inhibiteur de kras |
WO2024081674A1 (fr) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Polythérapies pour le traitement du cancer |
Also Published As
Publication number | Publication date |
---|---|
CN114040914A (zh) | 2022-02-11 |
TW202115089A (zh) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021000885A1 (fr) | Dérivés de quinazoline, leur procédé de préparation et leur utilisation médicale | |
CN109219604B (zh) | 四氢异喹啉雌激素受体调节剂及其用途 | |
CN110511209B (zh) | 可用作激酶抑制剂的吲哚甲酰胺化合物 | |
CN107253963B (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
WO2020238791A1 (fr) | Dérivé d'hydropyridopyrimidine, son procédé de préparation et son utilisation médicale | |
CN112778276A (zh) | 作为shp2抑制剂的化合物及其应用 | |
JP2017518276A (ja) | ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物 | |
CN104540830A (zh) | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 | |
TWI623316B (zh) | Antitumor effect enhancer derived from pyrrolopyrimidine compound | |
CN113801114A (zh) | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 | |
JP6908536B2 (ja) | ムスカリンm2受容体の正のアロステリックモジュレーター | |
CN102372698A (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
WO2022268230A1 (fr) | Composé destiné à être utilisé en tant qu'inhibiteur de kif18a | |
WO2021249475A1 (fr) | Dérivé de quinazoline condensé, son procédé de préparation et son application en médecine | |
WO2021208918A1 (fr) | Composés tricycliques servant d'inhibiteurs d'egfr | |
CN113980032A (zh) | 稠合四环类衍生物、其制备方法及其在医药上的应用 | |
CN115867346A (zh) | 激酶抑制剂 | |
TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
WO2022166860A1 (fr) | Inhibiteur de pim kinase | |
WO2020169058A1 (fr) | Composé antagoniste de pd-l1 | |
WO2022156779A1 (fr) | Dérivé de pyrazolo[1,5-a]pyrimidine-7-amine substitué, et compositions et utilisation médicale de celui-ci | |
WO2023066371A1 (fr) | Composé tétracyclique contenant de l'azote, son procédé de préparation et son utilisation médicale | |
WO2021104413A1 (fr) | Dérivé de cycle pyridine fusionné, son procédé de préparation et son utilisation pharmaceutique | |
WO2022222911A1 (fr) | Composé pyrimidone et son utilisation | |
TW202214631A (zh) | 作為Akt激酶抑制劑的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20835037 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20835037 Country of ref document: EP Kind code of ref document: A1 |